Heart Failure, Diastolic
Conditions
Keywords
Exercise, Hemodynamics,, Heart failure
Brief summary
The global objective of this study is to determine the mechanisms of exercise intolerance and dyspnea on exertion (DOE) in patients with HFpEF and based on this pathophysiology, test whether specific exercise training programs (whole body vs single leg) will result in improved exercise tolerance.
Detailed description
This will be a randomized, non-blinded prospective intervention testing the effects of two types of exercise training, whole body and isolated single leg, on HFpEF patients with either central or peripheral limitations to exercise training. Subjects will undergo baseline maximal exercise testing and invasive right heart catheterization to define exercise tolerance and pulmonary and cardiac pressures during exercise. Based on the results of baseline testing, subjects will be divided into either centrally limited, defined as excessive rise in pulmonary capillary wedge pressure more than 25 mmHg that decreases after administration of sub-lingual nitroglycerin resulting in improved exercise tolerance, or peripherally limited, defined as no improvement in exercise tolerance despite reduction in pulmonary capillary wedge pressure after sublingual nitroglycerin. After baseline testing, subjects will be randomized to either whole body cycle exercise supplemented with sublingual nitroglycerin to improve training responsiveness or isolated single leg exercise training for 4 months. After 4 months, subjects will repeat maximal exercise testing and invasive right heart catheterization to assess responses to 4 months of exercise training.
Interventions
Exercise training, either whole body or isolated single leg
Sponsors
Study design
Intervention model description
HFpEF patients with either central or peripheral limitations to exercise will be randomly assigned to either whole body or isolated single leg exercise.
Eligibility
Inclusion criteria
* signs and symptoms of heart failure * an ejection fraction \> 0.50 * objective evidence of diastolic dysfunction
Exclusion criteria
* age \< 60 years * BMI \> 50 kg/m2 * PDE5 inhibitor use * Severe valvular disease * Severe COPD * CKD 4 or higher * Contra-indication to MRI.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Aerobic fitness | 4 months | Change in peak VO2 after exercise training |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiopulmonary hemodynamics | 4 months | Change in exercise pulmonary capillary wedge pressure |
| Sympathetic activity | 4 months | Change in muscle sympathetic activity |
| Leg blood flow | 4 months | Change in leg blood flow assessed by Doppler velocities in femoral artery |
| Cardiac fibrosis | 4 months | Change in T1 mapping times by cardiac MRI |
Countries
United States